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Abstract 
Human livers with histologically proven cirrhosis were assessed using in vitro 31p NMR spectroscopy. Spectra were compared with 
those from histologically normal ivers and showed significant elevations in phosphoethanolamine (PE) and phosphocholine (PC) and 
significant reductions in glycerophosphorylethanolamine (GPE) and glycerophosphorylcholine (GPC). There were no significant 
differences in spectra from livers with compensated and decompensated cirrhosis. These results help to characterise the alterations in 
membrane metabolism in cirrhosis of the liver. 
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1. Introduction 
The human liver responds to injury in broadly the same 
way, irrespective of the original causal agent [1]. Persistent 
alcohol abuse, viruses such as hepatitis B and hepatitis C, 
genetic disorders including haemochromatosis, Wilson's 
disease and a~-antitrypsin deficiency, cholestatic ondi- 
tions such as primary biliary cirrhosis and primary scleros- 
ing cholangitis, certain drugs and autoimmune diseases all 
may provoke a series of events that ultimately lead to 
cirrhosis or irreversible liver damage [2]. 
Cirrhosis of the liver is a diffuse process, characterised 
by the formation of fibrous tissue and regrowth of hepato- 
cytes in an abnormal nodular pattern [3]. Current assess- 
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ment methods of the functional state of liver injury in 
cirrhosis are not entirely satisfactory, usually depending on 
a severity index obtained from a collection of laboratory 
parameters and clinical findings [4-7]. 
Nuclear magnetic resonance (NMR) spectroscopy is a 
non-invasive technique, which can be used to provide 
localised biochemical information on hepatic metabolic 
processes in vivo. A typical 3~p NMR spectrum of the 
human liver in vivo contains resonances which may be 
assigned to phosphomonoesters (PME), phosphodiesters 
(PDE), inorganic phosphate (Pi) and nucleotide triphos- 
phates (NTP) [8-12]. 
The PME and PDE resonances in hepatic spectra are 
multicomponent and the constituents cannot as yet be 
completely resolved at the magnetic field strengths em- 
ployed in human in vivo NMR studies, despite the use of 
proton-decoupling techniques [13]. The PME resonance 
includes contributions from cell membrane precursors [14] 
and glycolytic intermediates [15]. The PDE resonance is 
also composite, containing information from cell mem- 
brane breakdown products [14] and from endoplasmic 
reticulum [16]. 
Previous human in vivo NMR studies have reported on 
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the elevation in PME/ATP and the reduction in PDE/ATP 
with increasing functional severity of cirrhosis [17,18]. 
However, the underlying metabolic abnormalities responsi- 
ble for these observations have not been fully investigated. 
In vitro NMR techniques on human tissue extracts have 
been successfully used to study the metabolite changes 
responsible for the in vivo PME and PDE signals in 
hepatic tumours and normal iver [ 15,1 9]. Although Menon 
and colleagues [18] reported on in vitro NMR findings 
from a small number of livers from patients with chronic 
liver disease, no systematic approach as been applied to 
the characterisation f the cirrhotic liver. 
Therefore, the aim of this study was to characterise the 
metabolic changes observed by in vitro 3Jp NMR in 
cirrhosis of the liver. The results are discussed in the 
context of previous in vivo hepatic 31p NMR findings. 
Table 1 
Laboratory data on the patients from whom the liver samples were 
collected 
Tissue type Serum Plasma Prothrombin Pugh's 
bilirubin albumin time score ~ 
(~mol / l )  (g/ l)  (s) (5-15) 
(5-17) + (35-50) + (12-14) + 
Compensated 177 40 14 7 
(n = 10) (35-460) (31-48) (13-16) (6-7) 
Decompensated 143 31 17 10 
(n = 15) (34-388) (22-40) (13-25) (8-12) 
Data are means (range values). 
Pugh's score [4] = functional severity of cirrhosis. Score < 7, compen- 
sated cirrhosis. Score > 8, decompensated cirrhosis. 
+ limits of reference range. 
All information was obtained preoperatively, on the day of liver trans- 
plantation. 
2. Materials and methods 
Standard percutaneous liver biopsies do not yield enough 
tissue for in vitro NMR studies, and therefore samples of 
cirrhotic liver were taken during surgery for orthotopic 
hepatic transplantation. Liver tissue was obtained from 25 
patients with histologically proven cirrhosis. Ten patients 
(40%) had primary biliary cirrhosis, seven (28%) post-viral 
cirrhosis, six (24%) primary sclerosing cholangitis, one 
(4%) Wilson's disease and one (4%) alcoholic cirrhosis. 
The severity of liver dysfunction was assessed using the 
Pugh's score [4], obtained from clinical and biochemical 
data, acquired on the day of liver transplantation. This is 
the standard scoring system, which is used clinically, 
grading liver injury from 5 (best function) to 15 (worst 
function), taken from information comprising serum biliru- 
bin, plasma albumin levels, prothrombin time and the 
presence/severity of ascites and hepatic encephalopathy. 
The 25 liver samples were categorised into two groups: 
functionally compensated cirrhosis with a Pugh's score 
_< 7 (n = 10) and functionally decompensated cirrhosis 
with a Pugh's score > 8 (n = 15)(Table 1). 
Permission for this study was obtained from the Ethics 
Committees of the Royal Postgraduate Medical School, 
London, and the Royal Free Hospital and School of 
Medicine, London. All patients provided written, informed 
consent. 
2.1. Sample collection 
Two investigators were present in the operating theatre 
to obtain tissue samples from each recipient liver. In every 
case, 6-8 representative sugar lump sized pieces of liver 
were freeze-clamped in liquid nitrogen with minimum 
possible ischaemic time (2-7 min). This was performed ex 
vivo within 3 min of hepatectomy in 22 cases. All samples 
were stored separately in a liquid nitrogen dewar until 
further processed. 
2.2. Reference data 
Reference data were obtained from wedge biopsy sam- 
ples of liver, taken from 6 patients undergoing iaparotomy 
for surgical treatment of pancreatitis. In each case, con- 
tiguous samples of liver tissue were found to be histologi- 
cally normal on examination [15]. 
2.3. Tissue extract preparation 
The wet weight of each sample was between 560 mg 
and 2310 mg. Twelve per cent perchloric acid (PCA) was 
added to the still-frozen samples, in a ratio of 5 ml/g of 
liver tissue. Each sample was ground down under liquid 
nitrogen with a mortar and pestle and then allowed to 
thaw, before centrifugation at 3000 rpm for 10 min. The 
supernatant was separated, neutralized with 3 M KOH, 
freeze-dried and reconstituted in D20. The pH was read- 
justed to 7.5, after the addition of 100 mmol/l  of EDTA to 
chelate any paramagnetic metal ions present. Absolute 
quantification of metabolites was achieved by adding 
known amounts of methylene diphosphonate (MDP) 
and/or phosphocreatine (PCr) to the perchloric acid ex- 
tracts. These acted as internal reference standards for 
chemical shift assignments of the resonances observed. 
2.4. NMR methods 
All NMR spectroscopy measurements were performed 
at room temperature. Proton-decoupled 31p NMR spectra 
were obtained using a high resolution NMR spectroscopy 
system (operating at l l.7T), from the perchloric acid 
extracts of liver tissue, with 16 K data points and a 45 ° 
pulse angle applied at intervals of 1 s. Corrections for T t 
relaxation were made using samples run with a repetition 
time of 20 s. Metabolites were assigned using the methods 
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we have previously described [15]. The chemical shift of 
each metabolite was found and subsequently confirmed by 
the use of 'spiking' with known compounds [15]. 
2.5. Data processing 
The free induction decay (FID) was zero filled to 32 K 
and Fourier transformed after line-broadening of 5 Hz. 
Peak areas for PE, PC, GPE, GPC, MDP and/or  PCr were 
obtained, using the NMR1 ® spectral processing program 
(New Methods Research, E. Syracuse, USA) on a SUN 
SPARCstation l0 (Sun Microsystems, Mountain View, 
CA, USA). The data were fitted to Lorentzian functions. 
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Fig. I. Typical proton-decoupled ~ P NMR spectrum of perchloric acid 
extract prepared from histologically normal liver tissue. (a) Full spectrum; 
(b) PME and PDE regions. Abbreviations: PME, phosphomonoesters; 
PDE, phosphodiesters; NAD, NADH+NAD; NTP, nucleotide triphos- 
phates; NDP, nucleotide diphosphate; PE, phosphoethanolamine; PC, 
phosphocholine; GPE, glycerophosphorylethanolamine; GPC, glyc- 
erophosphorylcholine; PCr (phosphocreatine) wasadded as an internal 
reference standard. This figure is modified from Bell et al. [15]. 
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Fig. 2. Typical proton decoupled ~lp NMR spectrum of perchloric acid 
extract from liver tissue with histologically proven cirrhosis. (a) Full 
spectrum, (b) PME and PDE regions. Abbreviations: PME, phosphomo- 
noesters; PDE, phosphodiesters; NAD, NADH + NAD; NTP, nucleotide 
triphosphates; NDP, nucleotide diphosphate: PE, phosphoethanolamine: 
PC, phosphocholine; GPE, glycerophosphorylethanolamine: GPC, glyc- 
erophosphorylcholine: PCr (phosphocreatine) and MDP (methylene 
diphosphonate) were added as internal reference standards. 
2.6. Statistical analysis 
Since the data were not normally distributed, non-para- 
metric statistical analysis was applied. Values for metabo- 
lite concentrations in the patient and reference populations 
were compared using the Mann-Whitney U-test. A P-value 
of < 0.05 was considered significant. All metabolite con- 
centrations are quoted as mean values + 1 standard evia- 
tion. 
3.  Resu l ts  
A typical 31p NMR spectrum from a PCA extract of 
normal liver contains resonances arising from PME, PDE, 
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Table 2 
Concentrations of metabolites obtained from in vitro 3~p NMR spectra from histologically normal and cirrhotic liver tissue 
Tissue type Metabolite concentrations ( /~mol /g  wet weight) 
PE PC GPE GPC 
Normal liver (n = 6) 
All cirrhosis (n = 25) 
Compensated cirrhosis (n = 10) 
Decompensated cirrhosis (n = 15) 
0.16 + 0.03 0.16 + 0.04 2.35 ± 0.46 2.46 + 0.37 
1.04 + 0.75 ~ 0.41 + 0.37 b 0.29 + 0.37 ~ 0.14 ± 0.26 ~ 
1 .28+0.70 ~ 0.38_+0.22 ~ 0.27 ± 0.31 ~ 0 .13±0.12  c 
0.88 ± 0.76 J 0.44 ± 0.45 ~ 0.30 ± 0.42 d 0.14 ± 0.29 d 
Data are mean values _ 1 S.D. 
Significant difference from the reference population: ~ P < 0.0005, b p < 0.05, c p < 0.0001, d p < 0.001, e p < 0.01. 
NTP, NDP and Pi (Fig. 1). The PME region of the 
spectrum consists of over 10 resonances, including signal 
from PE, PC, AMP,2,3-DPG, coenzyme A, glucose 6- 
phosphate, glycerol l-phosphate, 3-phosphoglycerate and 
ribose 5-phosphate [15-19]. The PDE region contains two 
major resonances, GPE and GPC [15,19-21]. 
Most of these resonances vary markedly with ischaemia 
and it was therefore only sensible to quantify the more 
stable compounds, namely PE and PC from the PME 
region and GPE and GPC from the PDE region of the 
spectrum [22-24]. 
The signal intensity of the PE and PC resonances was 
increased and the GPE and GPC resonances reduced in 
spectra from liver with histologically proven cirrhosis (Fig. 
2) when compared to spectra from histologically normal 
liver. The metabolite concentrations ( /zmol /g  wet weight 
of liver tissue) are summarised in Table 2. 
All cirrhotic livers showed significantly higher PE (1.04 
+ 0.75 vs 0.16 + 0.03; P < 0.0005) and PC concentrations 
(0.41 + 0.37 vs 0.16 + 0.04; P < 0,05) and significantly 
lower GPE (0.29 + 0.37 vs 2.35 + 0.46; P < 0.005) and 
GPC concentrations (0.14 + 0.26 vs 2.46___ 0.37; P < 
0.0001) than normal tissue (Table 2). 
There was no significant difference between PE, PC, 
GPE and GPC concentrations from livers with functionally 
compensated cirrhosis and those from livers from function- 
ally decompensated cirrhosis (Table 2). 
There were regional variations in metabolite concentra- 
tions when liver samples from different areas of the same 
liver were analysed. Table 3 illustrates these variations in 
metabolite levels in a patient with compensated cirrhosis. 
There was no correlation between individual biochemi- 
Table 3 
In vitro 31p NMR: Variations in metabolite concentrations obtained from 
different regions of the same liver 
Metabolite concentration Region 1 Region 2 Region 3 Region 4 
PE (0.09-0.24) * 1.34 1.76 3.72 1.85 
PC (0.11-0.23) * 0.43 0.77 0.91 1.13 
GPE ( 1.79-2.71 ) ~ 0 0 1.00 0.15 
GPC (2.09-2.83) * 0 0 0 0 
All values expressed as /xmol /g  wet weight of liver tissue. 
* Reference range. 
cal indices (serum bilirubin, plasma albumin and pro- 
thrombin time) or clinical parameters of liver dysfunction 
(presence of ascites and hepatic encephalopathy), mea- 
sured on the day of the transplant operation, and PE, PC, 
GPE and GPC concentrations from the liver extracts. 
4. Discussion 
This study used in vitro 31p NMR to describe the 
changes in aqueous oluble membrane components in liv- 
ers with histologically proven cirrhosis, compared to nor- 
mal human liver tissue. 
Several human in vivo 31p NMR studies of the liver 
have shown abnormalities in PME, PME/ATP, PME/PDE 
and PDE/ATP in patients with cirrhosis [17,18,25-27]. 
Two of these studies have correlated the functional sever- 
ity of liver injury in cirrhosis with an elevation in 
PME/ATP and a reduction in PDE/ATP [17,18]. 
Our study attempted to investigate the underlying 
metabolic hanges responsible for these in vivo spectral 
appearances in man. Unfortunately, a limitation of human 
tissue character±sat±on by in vitro methods is the unavoid- 
able period of ischaemia during biopsy collection. Only 
quantification of PE, PC, GPE and GPC was attempted, as 
the other metabolites that comprise the PME and PDE 
peaks are known to alter radically from the in vivo situa- 
tion during periods of ischaemia [15,19]. Hachisuka and 
colleagues [28] noted that in rat liver subjected to pro- 
longed periods of ischaemia beyond 30 min, PC and PE 
were relatively stable, while GPE and GPC decreased. 
However, post-mortem studies of human brain and animal 
liver have indicated that the levels of PE, PC, GPE and 
GPC are not significantly affected by periods of ischaemia 
of up to one hour [22-24]. In our study much shorter 
periods of ischaemia were encountered. Twenty-two f the 
25 tissue samples from cirrhotic liver were collected within 
3 min of hepatectomy, while in the three tissue samples the 
ischaemic period was up to 7 min. 
Comparison of the 31p NMR spectra of PCA extracts 
from cirrhotic liver and histologically normal tissue showed 
increased concentrations of PE and PC and decreased 
concentrations of GPE and GPC from the diseased tissue. 
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Regional variations in metabolite concentrations were ob- 
served from samples obtained from different areas of each 
individual iver. 
Our results suggest hat increased concentrations of PE 
and PC may be responsible for elevation in PME/ATP  
observed in vivo [17,18,27]. Similarly, the reduction of 
PDE/ATP  seen in vivo [17,18] may be explained, at least 
in part by the reduction in GPE and GPC which we have 
noted. Endoplasmic reticulum is also an important compo- 
nent of the PDE resonance in vivo [16,29], but its relative 
contribution in the human cirrhotic liver is unclear and 
requires further study. 
The predominant contribution of PC and PE are as 
intermediates on the pathway of phospholipid biosynthesis 
[14]. GPE and GPC are phospholipid breakdown products 
[14]. Increased PE [30-33] and PC [34] have been ob- 
served in the regenerating rat liver and in other conditions 
of rapid cellular proliferation, such as in hepatic tumours 
[15,19,35]. Lymphomatous infiltration of the liver is also 
associated with elevated PE levels [35]. 
The hallmark of cirrhosis is abnormal regrowth of liver 
tissue in a nodular pattern. This occurs in the presence of 
increased fibroblastic activity [3]. The increase in PE and 
PC in our study may therefore be due to increased cell 
turnover as the cirrhotic liver attempts to regenerate. Either 
hepatocyte regeneration or the laying down of fibrous 
tissue, during the cirrhotic process, may be responsible for 
this phenomenon. 
GPE and GPC levels are reduced in rapidly proliferat- 
ing cells [15,19,32,33] and, in conditions of increased cell 
turnover such as the failing cirrhotic liver, it may be 
reasonable to expect reduced levels of these cell membrane 
degradation products. 
Unlike the in vivo studies where there was an elevation 
in PME/ATP  and PDE/ATP ,  correlated with the func- 
tional severity of liver injury [17,18], there was no statisti- 
cal difference between metabolite levels from functionally 
compensated and functionally decompensated cirrhotic 
liver in our study. This may partially reflect the arbitrary 
nature of the clinical grading system [4], which is subject 
to a number of extrahepatic influences. Furthermore, the 
regional variation in metabolites concentrations that we 
observed within each individual liver highlights the fact 
that cirrhosis is not a uniform process. Therefore, the lack 
of distinction between liver samples from patients with 
compensated and decompensated cirrhosis may also be a 
reflection of the varying composition of these tissue sam- 
ples. 
Further studies correlating in vivo 3Jp NMR spectral 
abnormalities with in vitro 3Jp NMR appearances and 
electron microscopy of liver tissue to assess the NMR 
contribution of endoplasmic reticulum are required. How- 
ever, the results of this study suggest hat the changes in 
PE, PC, GPE and GPC are responsible, to a large extent, 
for the PME/ATP  and PDE/ATP  abnormalities seen in 
patients with cirrhosis of the liver. 
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